PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31188588-2	2019	We report here two GALNS pharmacological chaperones, ezetimibe and pranlukast, identified by molecular docking-based virtual screening.	Ezetimibe	53-62	galactosamine (N-acetyl)-6-sulfatase	Homo sapiens	19-24	
31188588-6	2019	Combined treatment of recombinant GALNS with ezetimibe or pranlukast produced an additive effect.	Ezetimibe	45-54	galactosamine (N-acetyl)-6-sulfatase	Homo sapiens	34-39	
31188588-7	2019	Altogether, the results demonstrate that ezetimibe and pranlukast can increase the yield of recombinant GALNS and be used as a monotherapy or combination therapy to improve the therapeutic efficacy of MPS IVA enzyme replacement therapy.	Ezetimibe	41-50	galactosamine (N-acetyl)-6-sulfatase	Homo sapiens	104-109